Therapeutic Drug Monitoring of Intravenous Busulfan and Analytical Challenges due to the Drug Formulation Excipient PEG 400: Letter to the Editor

Ther Drug Monit. 2024 Jun 1;46(3):416-417. doi: 10.1097/FTD.0000000000001209. Epub 2024 Apr 16.

Authors

Nils Tore Vethe^{1

2}, Anders Mikal Andersen¹, Tobias Gedde-Dahl^{3

4}, Jochen Büchner⁵, Stein Bergan^{1

2}

Affiliations

¹ Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
² Department of Pharmacy, University of Oslo, Oslo, Norway.
³ Department of Hematology, Section for Stem Cell Transplantation, Oslo University Hospital, Oslo, Norway.
⁴ Institute for Clinical Medicine, University of Oslo, Oslo, Norway.
⁵ Department of Pediatric Hematology and Oncology, Oslo University Hospital, Oslo, Norway.

PMID: 38648662
DOI: 10.1097/FTD.0000000000001209

No abstract available

Publication types

Letter

MeSH terms

Administration, Intravenous
Busulfan* / administration & dosage
Busulfan* / blood
Busulfan* / pharmacokinetics
Drug Monitoring* / methods
Excipients*
Humans
Polyethylene Glycols*

Substances

Busulfan
Polyethylene Glycols
Excipients